Large Molecule Drug Substance CDMO Market 2023 – 2030 Size, Share & Trends Analysis Report by Source, by End-user, by Region, And Segment Forecasts, Service (Contract Manufacturing, Contract Development) - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits

Industry : Electronics & Semiconductors | Pages : 173 Pages | Published On : Jul 2023

The market size of the global contract development and manufacturing organization (CDMO) for large molecule drug substances reached USD 11.5 billion in 2022 and is projected to grow at a CAGR of 9.3% from 2023 to 2030. The market is driven by factors such as increasing approvals of large molecule drugs, particularly by the FDA, the growing prevalence of infectious diseases, rising demand for innovative therapeutics, and significant investments by pharmaceutical and biotech companies in advanced technologies to form partnerships with CDMOs. The value of large molecule drug investments was already rising before the COVID-19 pandemic, offering numerous new treatment possibilities. However, during the pandemic, the importance of biologics became even more apparent in the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. This resulted in a substantial increase in demand for CGMP drug substance and product manufacturing services, especially from CDMOs capable of offering various COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Nevertheless, the pandemic necessitated the adoption of new technologies in distribution logistics, vaccine production, monoclonal antibody manufacturing, and diagnostic testing. It emphasized the significance of local contract pharmaceutical services based in the US and the need for close collaboration among academia, manufacturers, drug innovators, and regulatory agencies to deliver treatments to patients. As CDMOs strive to develop COVID-19-related therapies in 2021, there is expected to be a continued constraint on large molecule (drug substance and drug product) production capacity and supply chains.

The development of large molecule drugs is divided into two stages: drug substance (DS) development, which includes the creation of master and working cell banks, process development, and scale-up, and drug product (DP) development, which involves filling the drug substance into primary containers. Regulatory authorities, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), provide guidance on the characterization and measurement of drug performance and quality. ICH Q6 specifically focuses on establishing specifications for both DS and DP for new chemical entities.

Developing an effective and safe large molecule drug substance while managing costs and development time is a challenging task. Formulation development encounters numerous difficulties due to the complexity and delicacy of large molecule active compounds. Overcoming these challenges and meeting deadlines have become key drivers for CDMOs in the early stages of drug development. There are various innovative technologies available to drug developers that aid in stabilization and protection of the large molecule drug substance, such as encapsulation and the use of buffers.

Service Insights:

The contract manufacturing segment was the dominant segment in the market, accounting for over 65.0% of the revenue in 2022. It is further divided into target identification and screening, target validation and functional informatics, lead identification and candidate optimization, and preclinical development. Indian pharmaceutical companies have extensive experience in contract manufacturing, and recent quality-control scrutiny has led to significant improvements in manufacturing standards.

The contract development segment is expected to have the highest compound annual growth rate (CAGR) of 10.9% over the forecast period. It is further divided into cell line development and process development. Top CDMOs offer services for large molecules, including upstream processing, downstream processing, and a portfolio of analytical methods for protein characterization and bioassays.

End-user Insights:

In 2022, biotech companies held the largest revenue share, accounting for over 40.0%. This can be attributed to increased research and development (R&D) investments in the biopharmaceutical sector and the growing number of diseases being extensively researched by biotech companies. Biotech firms are utilizing strategies such as mergers and acquisitions, regional expansion, product/service portfolio expansion, and competitive pricing to remain competitive and increase their market share.

The "others" segment is expected to have the highest CAGR of 10.7% over the forecast period. It includes pharmaceutical companies, government research institutes, and academic institutes. While traditional pharmaceutical companies focused on small molecules and biotechnology firms focused on large molecules, big pharma companies are now placing more emphasis on large molecules than small molecules.

Source Insights:

The mammalian source segment dominated the global market, accounting for a revenue share of over 55.0% in 2022. It is projected to have the fastest growth rate over the forecast period. This segment will expand as more complex biologics, such as bi- and tri-specific antibodies and antibody-drug conjugates, are developed. Monoclonal antibodies (mAbs) and their synthetic equivalents have received significant funding due to their effectiveness in treating various diseases, including cancer. Mammalian therapies have traditionally been used to develop mAbs for such diseases.

The microbial source segment is expected to register the second-highest CAGR during the forecast period. Microbial systems are widely used for producing recombinant proteins for therapeutic purposes. To date, around 650 protein drugs have been approved worldwide, with approximately 400 of them obtained from microbial recombinant technologies. Additionally, about one-third of biologics approved for manufacturing are produced using microbial sources, primarily for cytokines, hormones, enzymes, and mAbs. These factors contribute to the growth of this segment.

Regional Insights:

Asia Pacific held the largest revenue share of over 35.0% in 2022 and is projected to have the fastest CAGR over the forecast period. Factors driving the regional market growth include a large patient base, lower overall costs, a skilled workforce, and changes in the regulatory scenario. The region is considered highly attractive for contract manufacturing, with Asia Pacific countries having a substantial patient base and potential for highly skilled medical professionals. The cost of manufacturing and conducting clinical trials is significantly lower compared to Western countries. Companies like Boehringer Ingelheim and Wuxi Biologics are actively expanding their services in this region, with Wuxi Biologics launching a biologics integrated innovation center in China in November 2020. These factors are expected to contribute to the growth of the regional market.

North America is expected to witness growth in the coming years due to significant R&D investments in the United States. American pharmaceutical companies spent $102.3 billion on R&D in 2021, with a large portion allocated domestically. The presence of major players such as Catalent, Cambrex Corporation, LabCorp Drug Development, and Fujifilm Diosynth Biotechnologies also drives the market. For example, Catalent announced a multi-year investment of USD 350 million in April 2022 to expand large molecule drug product and drug substance manufacturing capabilities at its facility in Bloomington, Indiana.

Key Companies & Market Share Insights

Key market players employed strategies such as mergers, acquisitions, and partnerships to maintain their market share. For example, in September 2022, FUJIFILM Diosynth announced the expansion of its large-scale microbial manufacturing facility in Billingham, U.K. This expansion aims to cater to the increasing demand for microbial development and manufacturing. Some notable players in the global market for large molecule drug substance CDMOs include:

• Eurofins Scientific
• WuXi Biologics
• Samsung Biologics
• Catalent, Inc.
• Rentschler Biopharma SE
• AGC Biologics
• Recipharm AB
• Siegfried Holding AG
• Boehringer Ingelheim
• FUJIFILM Diosynth Biotechnologies

Global Large Molecule Drug Substance CDMO Market Segmentation

The report provides revenue growth forecasts at the global, regional, and country levels. It also offers an analysis of the latest industry trends and opportunities within each of the sub-segments from 2018 to 2030. The global large molecule drug substance CDMO market report is segmented based on service, source, end-user, and region, as analyzed by MarketDigits.

Service Outlook (Revenue, USD Million, 2018 - 2030)
• Contract Manufacturing
o Clinical
o Commercial
• Contract Development
o Cell Line Development
o Process Development

Source Outlook (Revenue, USD Million, 2018 - 2030)
• Mammalian
• Microbial
• Others

End-user Outlook (Revenue, USD Million, 2018 - 2030)
• Biotech Companies
• Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
o Rest of Europe
• Asia Pacific
o JapanChina
o India
o Australia
o Thailand
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East & Africa
o South Africa
o Saudi Arabia
o Kuwait
o Rest of Middle East and Africa


Table and Figures


At MarketDigits, we take immense pride in our 360° Research Methodology, which serves as the cornerstone of our research process. It represents a rigorous and comprehensive approach that goes beyond traditional methods to provide a holistic understanding of industry dynamics.

This methodology is built upon the integration of all seven research methodologies developed by MarketDigits, a renowned global research and consulting firm. By leveraging the collective strength of these methodologies, we are able to deliver a 360° view of the challenges, trends, and issues impacting your industry.

The first step of our 360° Research Methodology™ involves conducting extensive primary research, which involves gathering first-hand information through interviews, surveys, and interactions with industry experts, key stakeholders, and market participants. This approach enables us to gather valuable insights and perspectives directly from the source.

Secondary research is another crucial component of our methodology. It involves a deep dive into various data sources, including industry reports, market databases, scholarly articles, and regulatory documents. This helps us gather a wide range of information, validate findings, and provide a comprehensive understanding of the industry landscape.

Furthermore, our methodology incorporates technology-based research techniques, such as data mining, text analytics, and predictive modelling, to uncover hidden patterns, correlations, and trends within the data. This data-driven approach enhances the accuracy and reliability of our analysis, enabling us to make informed and actionable recommendations.

In addition, our analysts bring their industry expertise and domain knowledge to bear on the research process. Their deep understanding of market dynamics, emerging trends, and future prospects allows for insightful interpretation of the data and identification of strategic opportunities.

To ensure the highest level of quality and reliability, our research process undergoes rigorous validation and verification. This includes cross-referencing and triangulation of data from multiple sources, as well as peer reviews and expert consultations.

The result of our 360° Research Methodology is a comprehensive and robust research report that empowers you to make well-informed business decisions. It provides a panoramic view of the industry landscape, helping you navigate challenges, seize opportunities, and stay ahead of the competition.

In summary, our 360° Research Methodology is designed to provide you with a deep understanding of your industry by integrating various research techniques, industry expertise, and data-driven analysis. It ensures that every business decision you make is based on a well-triangulated and comprehensive research experience.

Choose License Type
  • Tailored advice to Drive your Performance
  • Product Planning Strategy
  • New Product Stratergy
  • Expanded Research Scope
  • Comprehensive Research
  • Strategic Consulting
  • Provocative and pragmatic
  • Accelerate Revenue & Growth
  • Evaluate the competitive landscape
  • Optimize your partner network
  • Analyzing industries
  • Mapping trends
  • Strategizing growth
  • Implementing plans
A comprehensive cogent custom study with Analyzing Industries, Mapping Trends, Straterging growth & Implementing Plans. An in-depth and breadth of composite research, which gives complete support of the generation and evaluation of growth opportunities, and best practices recognition to help increase the revenue. Request a Custom Research below.
Request Customization

Covered Key Topics

Growth Opportunities

Market Growth Drivers

Leading Market Players

Company Market Share

Market Size and Growth Rate

Market Trend and Technological

Research Assistance

We will be happy to help you find what you need. Please call us or write to us:

+1 510-730-3200 (USA Number)